- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 15
- States / cities
- La Jolla, California • San Francisco, California • Torrance, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 32 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Sarcoidosis-associated Pulmonary Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- i.v. selexipag, oral selexipag (Uptravi)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- La Jolla, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Interventions
- LIQ861 (treprostinil) inhalation powder
- Combination Product
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Georgia
- Conditions
- Cardiodynamics, Safety, Tolerability, Pharmacokinetics
- Interventions
- selexipag, placebo for selexipag, moxifloxacin, moxifloxacin-matching placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- selexipag (Uptravi)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Iowa City, Iowa • Seattle, Washington
- Conditions
- Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 32
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan, Tadalafil, Selexipag
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 15
- States / cities
- Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more